Comparison of placental growth factor and fetal flow Doppler ultrasonography to identify fetal adverse outcomes in women with hypertensive disorders of pregnancy: An observational study

BMC Pregnancy and Childbirth

Volumn 13, Issue , 2013, Pages

  Molvarec, Attila ^a   Gullai, Nóra ^a   Stenczer, Balázs ^a   Fügedi, Gergely ^a   Nagy, Bálint ^a   Rigó, János ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Doppler; Growth restriction; Hypertension; IUGR; Placental growth factor; PlGF; Preeclampsia

Indexed keywords

PLACENTAL GROWTH FACTOR;

ADULT; ARTICLE; DESCENDING AORTA; DOPPLER ECHOGRAPHY; DOPPLER FLOWMETRY; FEMALE; FETUS CIRCULATION; FETUS OUTCOME; HELLP SYNDROME; HUMAN; HYPERTENSION; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; NEWBORN; OBSERVATIONAL STUDY; PREECLAMPSIA; PREMATURE LABOR; PRENATAL GROWTH; UMBILICAL ARTERY;

ADULT; AORTA; FEMALE; FETAL GROWTH RETARDATION; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; PREGNANCY; PREGNANCY PROTEINS; PREMATURE BIRTH; REGIONAL BLOOD FLOW; ULTRASONOGRAPHY, DOPPLER; UMBILICAL ARTERIES;

EID: 84881273858     PISSN: None     EISSN: 14712393     Source Type: Journal    
DOI: 10.1186/1471-2393-13-161     Document Type: Article

References (29)

1. National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000, 183:S1-S22. National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy.
2. Walker JJ. Pre-eclampsia. Lancet 2000, 56:1260-1265.
3. Gardosi J, Madurasinghe V, Williams M, Malik A, Francis A. Maternal and fetal risk factors for stillbirth: population based study. Brit Med J 2013, 346:f108. 10.1136/bmj.f108, 3554866, 23349424.
4. Knudsen UB, Kronborg CS, von-Dadelszen P, Kupfer K, Lee S-W, Vittinghus E, Allen JG, Redman CW. A single rapid point of care placental growth factor determination as an aid in the diagnosis of preeclampsia. Pregnancy Hypertens 2012, 2:8-15.
5. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672-683. 10.1056/NEJMoa031884, 14764923.
6. Hertig A, Berkane N, Lefevre G, Toumi K, Marti HP, Capeau J, Uzan S, Rondeau E. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004, 50:1702-1703. 10.1373/clinchem.2004.036715, 15331514.
7. McKeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004, 191:1240-1246. 10.1016/j.ajog.2004.03.004, 15507947.
8. Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, Crombleholme WR, Ness RB, Roberts JM, Hubel CA. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005, 90:4895-4903. 10.1210/jc.2004-1955, 15886253.
9. Kim SY, Ryu HM, Yang JH, Kim MY, Han JY, Kim JO, Chung JH, Park SY, Lee MH, Kim DJ. Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia. J Korean Med Sci 2007, 22:873-877. 10.3346/jkms.2007.22.5.873, 2693856, 17982238.
10. Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998, 179:1539-1544. 10.1016/S0002-9378(98)70021-3, 9855593.
11. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003, 188:177-182. 10.1067/mob.2003.111, 12548214.
12. Reuvekamp A, Velsing-Aarts FV, Poulina IE, Capello JJ, Duits AJ. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 1999, 106:1019-1022. 10.1111/j.1471-0528.1999.tb08107.x, 10519425.
13. Livingston JC, Chin R, Haddad B, McKinney ET, Ahokas R, Sibai BM. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol 2000, 183:1554-1557. 10.1067/mob.2000.108022, 11120527.
14. Sunderji S, Gaziano E, Wothe D, Rogers LC, Sibai B, Karumanchi SA, Hodges-Savola C. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 2010, 202:40:e1-7.
15. De-Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'Anna R. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008, 87:837-842. 10.1080/00016340802253759, 18607829.
16. Ohkuchi A, Hirashima C, Suzuki H, Takahashi K, Yoshida M, Matsubara S, Suzuki M. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res 2010, 33:422-427. 10.1038/hr.2010.15, 20150910.
17. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, Gotsch F, Edwin SS, Gomez R, Yeo L, Conde-Agudelo A, Hassan SS. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009, 22:1021-1038. 10.3109/14767050902994754, 3427777, 19900040.
18. Lim JH, Kim SY, Park SY, Yang JH, Kim MY, Ryu HM. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol 2008, 111:1403-1409. 10.1097/AOG.0b013e3181719b7a, 18515525.
19. Molvarec A, Szarka A, Walentin S, Szucs E, Nagy B, Rigo J. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertens Res 2010, 33:892-898. 10.1038/hr.2010.92, 20535121.
20. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010, 202:161:e1-11.
21. Powers RW, Jeyabalan A, Clifton RG, Van-Dorsten P, Hauth JC, Klebanoff MA, Lindheimer MD, Sibai B, Landon M, Miodovnik M, Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One 2010, 5:e13263. 10.1371/journal.pone.0013263, 2952583, 20948996, Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network.
22. Nadarajah VD, Min RG, Judson JP, Jegasothy R, Ling EH. Maternal plasma soluble fms-like tyrosine kinase-1 and placental growth factor levels as biochemical markers of gestational hypertension for Malaysian mothers. J Obstet Gynaecol Res 2009, 35:855-863. 10.1111/j.1447-0756.2009.01037.x, 20149032.
23. Khalil A, Muttukrishna S, Harrington K, Jauniaux E. Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS One 2008, 3:e2766. 10.1371/journal.pone.0002766, 2447877, 18648513.
24. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012, 206:58:e1-8.
25. Gullai N, Stenczer B, Molvarec A, Fugedi G, Veresh Z, Nagy B, Rigo J. Evaluation of a rapid and simple placental growth factor test in hypertensive disorders of pregnancy. Hypertens Res 2013, 36:457-462. 10.1038/hr.2012.206, 23324863.
26. Chaiworapongsa T, Romero R, Korzeniewski SJ, Cortez JM, Pappas A, Tarca AL, Chaemsaithong P, Dong Z, Yeo L, Hassan SS. Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Matern Fetal Neonatal Med in press. http://dx.doi.org/10.3109/14767058.2013.806905.
27. Saffer C, Olson G, Boggess KA, Beyerlein R, Eubank C, Sibai BM, the NORMALS Study Group Determination of placental growth factor (PlGF) levels in healthy pregnant women without signs or symptoms of preeclampsia. Pregnancy Hypertens 2013, 3:124-132. the NORMALS Study Group.
28. Benton SJ, Hu Y, Xie F, Kupfer K, Lee SW, Magee LA, von-Dadelszen P. Can placental growth factor in maternal circulation identify fetuses with placental intrauterine growth restriction?. Am J Obstet Gynecol 2012, 206:163:e1-7.
29. Schlembach D, Wallner W, Sengenberger R, Stiegler E, Mortl M, Beckmann MW, Lang U. Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2007, 29:407-413. 10.1002/uog.3930, 17330322.